| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular and Environmental Toxicology Program (J.H.G., L.A.S.) and Department of Comparative Biosciences (D.E.R., M.D.S., J.J.W., L.A.S.), University of Wisconsin-Madison, Madison, Wisconsin 53706
Address all correspondence and requests for reprints to: L. A. Schuler, Department of Comparative Biosciences, University of Wisconsin, 2015 Linden Drive, Madison, Wisconsin 53706. E-mail: schulerl{at}svm.vetmed.wisc.edu.
The importance of prolactin (PRL) in physiological proliferation and differentiation of the mammary gland, together with high levels of PRL receptors in breast tumors, the association of circulating PRL with incidence of breast cancer, and the recognition of locally produced PRL, point to the need for greater understanding of PRL actions in mammary disease. Although PRL has been shown to activate multiple kinase cascades in various target cells, relatively little is known of its signaling pathways in the mammary gland apart from the Janus kinase 2/ signal transducer and activator of transcription 5 pathway, particularly in tumor cells. Another potential effector is activating protein-1 (AP-1), a transcription complex that regulates processes essential for neoplastic progression, including proliferation, survival and invasion. We demonstrate that PRL activates AP-1 in MCF-7 cells, detectable at 4 h and sustained for at least 24 h. Although Janus kinase 2 and ERK1/2 are the primary mediators of PRL-induced signals, c-Src, phosphatidylinositol 3'-kinase, protein kinase C, and other MAPKs contribute to maximal activity. PRL activation of these pathways leads to increased c-Jun protein and phosphorylation, JunB protein, and phosphorylation of c-Fos, elevating the levels of AP-1 complexes able to bind DNA. These active AP-1 dimers may direct expression of multiple target genes, mediating some of PRL’s actions in mammary disease.
This article has been cited by other articles:
 |
|
 |
|
  P. W. Harvey, D. J. Everett, and C. J. Springall Adverse effects of prolactin in rodents and humans: breast and prostate cancer J Psychopharmacol, March 1, 2008; 22(2_suppl): 20 - 27. [Abstract] [PDF]
|
|
|
|
 |
|
 L. M. Neilson, J. Zhu, J. Xie, M. G. Malabarba, K. Sakamoto, K.-U. Wagner, R. A. Kirken, and H. Rui Coactivation of Janus Tyrosine Kinase (Jak)1 Positively Modulates Prolactin-Jak2 Signaling in Breast Cancer: Recruitment of ERK and Signal Transducer and Activator of Transcription (Stat)3 and Enhancement of Akt and Stat5a/b Pathways Mol. Endocrinol., September 1, 2007; 21(9): 2218 - 2232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Doll, J. Pfeilschifter, and A. Huwiler Prolactin upregulates sphingosine kinase-1 expression and activity in the human breast cancer cell line MCF7 and triggers enhanced proliferation and migration Endocr. Relat. Cancer, June 1, 2007; 14(2): 325 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P W Harvey, D J Everett, and C J Springall Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: role in breast and prostate cancer Human and Experimental Toxicology, July 1, 2006; 25(7): 395 - 404. [Abstract] [PDF]
|
|
|
|
 |
|
 Z. Nouhi, N. Chughtai, S. Hartley, E. Cocolakis, J.-J. Lebrun, and S. Ali Defining the Role of Prolactin as an Invasion Suppressor Hormone in Breast Cancer Cells Cancer Res., February 1, 2006; 66(3): 1824 - 1832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Gutzman, S. E. Nikolai, D. E. Rugowski, J. J. Watters, and L. A. Schuler Prolactin and Estrogen Enhance the Activity of Activating Protein 1 in Breast Cancer Cells: Role of Extracellularly Regulated Kinase 1/2-Mediated Signals to c-fos Mol. Endocrinol., July 1, 2005; 19(7): 1765 - 1778. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
